Health Care · Biotechnology
AbbVie: revenue, profit and dividends
In fiscal 2025, AbbVie had revenue of $61.2B, up 10.3% a year on average since 2015, and net income of $4.23B (6.9% of revenue). Its dividend per share has gone up 11 years in a row, to $6.65. It has 8% more shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · +8.6% vs 2024
- Ticker
- ABBV · NYSE
- Sector
- Health Care
- Sub-industry
- Biotechnology
- Headquarters
- North Chicago, Illinois
- Founded
- 2013 (1888)
- In the S&P 500 since
- December 31, 2012
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- AbbVie Inc. · CIK 0001551152
Revenue and net income
Revenue went from $17.4B in 2011 to $61.2B in 2025.
Diluted earnings per share
Diluted EPS went from $2.18 in 2011 to $2.36 in 2025. Ten-year growth: −2.8% a year.
Dividends per share
Raised 11 years in a row, every year from 2015 to 2025. Ten-year growth: 12.2% a year.
Shares outstanding
8.3% more shares in 2025 than in 2015 (1.64B → 1.77B): new shares outweighed buybacks.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $17.8B in 2025, 29.1% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Dividend | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $61.2B | $4.23B | 6.9% | $2.36 | $6.65 | 1.77B | $19B | $1.21B | $17.8B |
| 2024 | $56.3B | $4.28B | 7.6% | $2.39 | $6.29 | 1.77B | $18.8B | $974M | $17.8B |
| 2023 | $54.3B | $4.86B | 9.0% | $2.72 | $5.99 | 1.77B | $22.8B | $777M | $22.1B |
| 2022 | $58.1B | $11.8B | 20.4% | $6.63 | $5.71 | 1.78B | $24.9B | $695M | $24.2B |
| 2021 | $56.2B | $11.5B | 20.5% | $6.45 | $5.31 | 1.78B | $22.8B | $787M | $22B |
| 2020 | $45.8B | $4.62B | 10.1% | $2.72 | $4.84 | 1.67B | $17.6B | $798M | $16.8B |
| 2019 | $33.3B | $7.88B | 23.7% | $5.28 | $4.39 | 1.48B | $13.3B | $552M | $12.8B |
| 2018 | $32.8B | $5.69B | 17.4% | $3.66 | $3.95 | 1.55B | $13.4B | $638M | $12.8B |
| 2017 | $28.2B | $5.31B | 18.8% | $3.30 | $2.63 | 1.6B | $9.96B | $529M | $9.43B |
| 2016 | $25.6B | $5.95B | 23.2% | $3.63 | $2.35 | 1.63B | $7.04B | $479M | $6.56B |
| 2015 | $22.9B | $5.14B | 22.5% | $3.13 | $2.10 | 1.64B | $7.54B | $532M | $7.0B |
| 2014 | $20B | $1.77B | 8.9% | $1.10 | $1.75 | 1.61B | $3.55B | $612M | $2.94B |
| 2013 | $18.8B | $4.13B | 22.0% | $2.56 | $2.00 | 1.6B | $6.27B | $491M | $5.78B |
| 2012 | $18.4B | $5.28B | 28.7% | $3.35 | — | 1.58B | $6.34B | $333M | $6.01B |
| 2011 | $17.4B | $3.43B | 19.7% | $2.18 | — | 1.58B | $6.25B | $356M | $5.89B |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
About these figures
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Biotechnology companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.